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OBJECTIVES This prospective study tested the impact of beta-blocker treatment on currently used risk
predictors in congestive heart failure (CHF).
BACKGROUND Given the survival benefit obtained by beta-blockade, risk stratification by factors established
in the “pre–beta-blocker era” may be questioned.
METHODS The study included 408 patients who had CHF with left ventricular ejection fraction (LVEF)
45%, all treated with an angiotensin-converting enzyme inhibitor or angiotensin type 1
receptor antagonist, who were classified into those receiving a beta-blocker (n  165) and
those who were not (n  243). In all patients, LVEF, peak oxygen consumption (peakVO2),
plasma norepinephrine (NE) and N-terminal pro-brain natriuretic peptide (NT-proBNP)
levels were determined.
RESULTS Although the New York Heart Association functional class (2.2  0.7 vs. 2.3  0.7),
peakVO2 (14.4  5.2 ml/min per kg vs. 14.4  5.5 ml/min per kg) and NT-proBNP (337 
360 pmol/l vs. 434  538 pmol/l) were similar in the groups with and without beta-blocker
treatment, the group with beta-blocker treatment had a lower heart rate (68  30 beats/min
vs. 76  30 beats/min), lower NE (1.7  1.2 nmol/l vs. 2.5  2.2 nmol/l) and higher LVEF
(24 10% vs. 21 9%; all p 0.05). Within one year, 34% of patients without beta-blocker
treatment, but only 16% of those with beta-blocker treatment (p  0.001), reached the
combined end point, defined as hospital admission due to worsening CHF and/or cardiac
death. A beneficial effect of beta-blocker treatment was most obvious in the advanced stages
of CHF, because the end-point rates were markedly lower (all p  0.05) in the group with
beta-blocker treatment versus the group without it, as characterized by peakVO210 ml/min
per kg (26% vs. 64%), LVEF 20% (25% vs. 45%), NE 2.24 nmol/l (18% vs. 40%) and
NT-proBNP 364 pmol/l (27% vs. 45%), although patients with beta-blocker treatment
received only 37  21% of the maximal recommended beta-blocker dosages.
CONCLUSIONS The prognostic value of variables used for risk stratification of patients with CHF is markedly
influenced by beta-blocker treatment. Therefore, in the beta-blocker era, a re-evaluation of
the selection criteria for heart transplantation is warranted. (J Am Coll Cardiol 2002;39:
1615–22) © 2002 by the American College of Cardiology Foundation
Beta-blockade has been shown in several controlled trials to
improve the prognosis and to reduce the cardiovascular
hospitalization rate in patients with symptomatic congestive
heart failure (CHF) (1–4). On the basis of these trials,
beta-blocker treatment has been included in the current
guidelines for CHF therapy and is now strongly recom-
mended as standard therapy for all patients with CHF and
systolic dysfunction (5,6). Long-term beta-blockade has
consistently been shown to increase left ventricular ejection
fraction (LVEF) in patients with CHF, whereas functional
capacity, as determined by the New York Heart Association
(NYHA) functional class, the 6-min walk test or peak
oxygen consumption (peakVO2), derived from cardiopulmo-
nary exercise testing, is not or only marginally improved
(7,8). The plasma concentrations of norepinephrine (NE)
decrease slightly with long-term beta-blocker treatment (9),
whereas reports on plasma concentrations of brain natri-
uretic peptides are inconsistent (10). Left ventricular ejec-
tion fraction, peakVO2 and NE (11), as well as brain
natriuretic peptide and the N-terminal fragment of its
precursor molecule (NT-proBNP) (12), have been proposed
as independent predictors of survival in patients with CHF.
However, most studies evaluating the prognostic variables in
CHF have been carried out in study groups in which only a
minority of patients were treated with beta-blockers. Be-
cause of the nonuniform effect of beta-blocker treatment on
survival, on the one hand, and on potential risk predictors,
on the other hand, the prognostic value of established risk
factors era may be questioned in the beta-blocker.
The purpose of the present study was to evaluate the
impact of beta-blocker treatment on the utility of estab-
lished variables for risk stratification in ambulatory patients
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with CHF. Specifically, the study sought to examine whether
the prognostic impact of peakVO2, LVEF, NE and NT-
proBNP is altered by concomitant beta-blocker treatment.
METHODS
Study group. The study included 408 consecutively en-
rolled patients with chronic CHF (NYHA functional
classes I to IV, 70 years old) and LVEF 45%. All
patients were referred to the Department of Cardiology at
the Medical Clinic of the University of Heidelberg for
assessment of their heart failure status and/or evaluation of
their potential candidacy for heart transplantation between
November 1994 and January 2000. The etiology of CHF
(dilated or ischemic cardiomyopathic) was confirmed by
cardiac catheterization before inclusion into the study.
Treatment (number of patients, mean percentage  SD the
recommended daily dose) with an angiotensin-converting
enzyme (ACE) inhibitor (n  397, 53  37%) or an
angiotensin type 1 (AT1) receptor antagonist (n 11, 48
21%) was defined as a mandatory inclusion criterion. The
subgroup of patients with additional beta-blocker treatment
(n  165) received the following beta-blockers (number of
patients, mean percentage  SD the recommended daily
dose): metoprolol (n  75, 200 mg/day, 35  17%),
carvedilol (n  65, 25 mg twice daily, 33  22%), sotalol
(n  18, 160 mg twice daily, 57  20%), bisoprolol (n  5,
5 mg twice daily, 40  14%) and celiprolol (n  2,
200 mg/day, 75  35%). All patients had to be in a stable
condition for at least four weeks, with the medication
individually optimized by the referring physician, before
assessment of the variables outlined subsequently. The study
conformed with the principles outlined in the Declaration
of Helsinki (13) and was approved by the institutional
Ethics Committee. All patients gave written, informed
consent.
Radionuclide ventriculography. Equilibrium rest radio-
nuclide ventriculography was performed with a multicrystal
gamma camera (Orbiter, Siemens, Erlangen, Germany) in
the left anterior oblique view. Twenty minutes after pre-
treatment of red blood cells with 2 ml of stannous pyro-
phosphate, 30 mCi of technetium-99m (DuPont, Bad
Homburg, Germany) was rapidly injected, followed by data
acquisition and analysis (RNV, version 2.1, Elscint Medical
Technology, Vienna, Austria). The LVEF was derived from
time-activity curves as: (end-diastolic  end-systolic
counts) / end-diastolic counts (14–16).
Table 1. Patient Characteristics
All Patients
(n  408)
Patients Without
Beta-Blocker Treatment
(n  243)
Patients With
Beta-Blocker Treatment
(n  165)
Age (yrs) 55  11 55  11 54  12
Gender (%male) 84 83 85
Ischemic cardiomyopathy (%) 30 22 42*
NYHA functional class 2.3  0.7 2.3  0.7 2.2  0.7
Rest heart rate (beats/min) 73  30 76  30 68  30*
Mean arterial pressure (mm Hg) 98  26 98  28 97  24
PeakVO2 (ml/kg per min) 14.4  5.3 14.4  5.5 14.4  5.2
LVEF (%) 22  10 21  9 24  10*
NE (nmol/l) 2.2  1.9 2.5  2.2 1.7  1.2*
NT-proBNP (pmol/l) 395  476 434  538 337  360
Medications (%)
ACE inhibitor 97 99 94*
AT1 receptor antagonist 3 1 6*
Beta-blocker 40 0 100
Digitalis glycoside 70 75 62*
Diuretic 86 91 79*
Warfarin 76 74 80
Amiodarone 7 10 4*
ICD 18 17 21
*p  0.05 compared with patients without beta-blocker treatment. Data are presented as the mean value  SD or percentage
of patients.
ACE  angiotensin-converting enzyme; AT1  angiotensin type 1; ICD  intracardiac defibrillator; LVEF  left
ventricular ejection fraction; NE  norepinephrine; NT-proBNP  N-terminal pro-brain natriuretic peptide; NYHA  New
York Heart Association; PeakVO2  peak oxygen consumption.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AT1  angiotensin type 1 receptor
CHF  congestive heart failure
LVEF  left ventricular ejection fraction
NE  norepinephrine
NT-proBNP  N-terminal pro-brain natriuretic peptide
NYHA  New York Heart Association
PeakVO2  peak oxygen consumption
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Exercise testing. A symptom-limited cardiopulmonary ex-
ercise test was performed to determine peakVO2. The
cardiopulmonary exercise test equipment included a meta-
bolic cart (Oxycon-alpha, Jaeger, Wu¨rzburg, Germany)
with a bicycle ergometer (Ergoline, Jaeger). Details of the
test protocol have been published previously (14–16).
Neurohormonal variables. After insertion of an intrave-
nous cannula and 30 min in the supine position, 2 ml of
venous blood was drawn (EDTA-containing tubes,
Sarstedt, Nu¨mbrecht, Germany) and immediately centri-
fuged, and the plasma was stored at 30°C. The plasma
concentrations of NT-proBNP and NE were analyzed by
enzyme-linked immunosorbent assay (12) and radioenzy-
matic assay (14), respectively.
Clinical follow-up. The combined study end point was
defined as progressive heart failure requiring hospital ad-
mission, with intravenous inotropic, diuretic or mechanical
support and/or cardiac death within one year. Patients who
received a heart transplant during the one-year follow-up
period were considered as survivors until the date of trans-
plantation (15). Information on hospital periods and the
circumstances of death was obtained from the hospital’s
medical records or the referring physician.
Statistical analysis. The data are presented as the mean
value  SD, except where otherwise specified. Repeated
measures analysis of variance on ranks was performed. The
design included the intergroup factor (i.e., with or without
beta-blocker treatment) and repeated measurements of the
intragroup factors (i.e., NYHA functional class, rest heart
rate, mean arterial pressure, peakVO2, LVEF, NE and
NT-proBNP). Analysis of available cases was done. The
highly significant interaction term of “group–measure” (F
7.17, df  7.1995; p  0.0001; Greenhouse-Geisser–
corrected p value) strongly indicated that differences be-
tween the groups were restricted to some of the measures
studied. To work out the locus of the interaction (i.e., at
which measure the groups differed), a series of nonparamet-
ric two-sample Wilcoxon tests was performed. To test for
significant differences between mean values, the two-sample
Wilcoxon test was also used. To compare frequencies,
chi-square analysis was performed. A p value 0.05 was
considered statistically significant. Univariate and multivar-
iate Cox regression analyses were performed. Differences in
event-free survival were detected by the Kaplan-Meier
product limit method and compared by the Petro-Prentice
generalized log-rank test. Calculations were performed with
SAS version 6.12.
RESULTS
Patient characteristics. The clinical characteristics of the
enrolled patients are summarized in Table 1. Fifteen percent
of the patients were in NYHA functional class I, 41% in
class II, 42% in class III and 2% in class IV. The study group
Table 2. Analysis of the Combined Study End Point of Cardiac
Death or Hospital Admission Due to Worsening Heart Failure
Within 12 Months
Event-Free
Survival
Combined
End Point
Without beta-blocker treatment (n  243) 160 (66%) 83 (34%)
NYHA functional class 2.2  0.7 2.7  0.7*
PeakVO2 (ml/kg per min) 15.5  5.7 12.3  4.2*
LVEF (%) 22  9 18  8*
NE (nmol/l) 2.3  2.2 2.8  2.0
NT-proBNP (pmol/l) 330  385 633  712*
With beta-blocker treatment (n  165) 139 (84%) 26 (16%)†
NYHA functional class 2.2  0.7 2.5  0.5*
PeakVO2 (ml/kg per min) 14.9  5.4 11.5  2.3*
LVEF (%) 25  10† 18  9*
NE (nmol/l) 1.6  1.1† 2.1  1.6
NT-proBNP (pmol/l) 297  345 550  370*
*p  0.05 compared with event-free survival. †p  0.05 compared with patients
without beta-blocker treatment. Data are presented as the number (%) of patients or
mean value  SD.
Abbreviations as in Table 1.
Figure 1. Kaplan-Meier analysis of the 12-month, event-free survival rates of 165 patients with congestive heart failure treated with beta-blockers and 243
patients without beta-blocker treatment.
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was divided into two cohorts: one with (n  165, 40%) and
one without (n  243, 60%) beta-blocker treatment, in
addition to an ACE inhibitor or an AT1 receptor antago-
nist. Age, gender, NYHA functional class, mean blood
pressure, peakVO2 and NT-proBNP were similar in both
groups. However, patients with beta-blocker therapy were
Figure 2. Frequency of combined end points within 12 months in congestive heart failure patients with (black bars) and without (white bars) beta-blocker
treatment, stratified by frequently applied cut-off values for peak oxygen consumption (peakVO2) and left ventricular ejection fraction (LVEF) or by tertiles
of norepinephrine and N-terminal pro-brain natriuretic peptide (NT-proBNP) (all p  0.05).
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characterized by a reduced rest heart rate, increased LVEF
and lower plasma concentrations of NE (Table 1).
Survival analysis. Independent of additional beta-blocker
treatment, patients reaching the study end point were
characterized by a lower peakVO2 and lower LVEF, as well
as a higher NYHA functional class and higher NT-proBNP
plasma levels, whereas NE plasma concentrations tended to
be higher (Table 2). However, beta-blocker–treated patients
had a significantly lower cardiac event rate, as compared
with patients without beta-blocker treatment (16% vs. 34%,
p  0.0001) (Fig. 1), although patients reaching the
combined study end point in both groups showed no
significant differences with respect to NYHA functional
class, peakVO2, LVEF and NT-proBNP plasma levels
(Table 2). Only 10 (6%) of 165 beta-blocker–treated pa-
tients, as compared with 40 (17%) of 243 patients without
additional beta-blocker treatment, died of cardiac causes
within one year (p  0.001). Similarly, a significantly lower
proportion of beta-blocker–treated patients were hospital-
ized due to worsening heart failure (12% vs. 24%, p 
0.005). Within the beta-blocker group, the mean daily
equivalent dosages of the diverse beta-blockers (35  17%
vs. 38  21%) and ACE inhibitors (52  32% vs. 59 
34%) was similar between those patients with and those
without a cardiac event. Patients treated with a beta-blocker
for more than three months and those treated less than three
months were not different in terms of their baseline values
(data not shown) or end point rate (15% vs. 16%). The
beneficial effect of beta-blocker therapy was seen through-
out the total patient group and was most obvious in patients
with severe CHF (Fig. 2). Compared with patients without
beta-blocker treatment, the cardiac event rates in beta-
blocker–treated patients were reduced not only in NYHA
functional classes I and II (10% vs. 20%, p  0.05), but also
in classes III and IV (18% vs. 30%, p 0.05). The beneficial
beta-blocker effect was independent of the CHF etiology
(data not shown).
Univariate and multivariate predictors of event-free sur-
vival. In the total group, univariate Cox regression analysis
revealed peakVO2, LVEF, NE and NT-proBNP as strong
risk predictors (Table 3). Because beta-blocker treatment
also predicted outcome, on univariate analysis, univariate
Cox regression analyses were separately performed for
patients with and those without additional beta-blocker
treatment. Hence, only NE failed to persist as a risk
predictor in both groups. PeakVO2, LVEF and NT-
proBNP continued to be independent predictors of a cardiac
event after multivariable Cox regression analysis in the total
study group. However, only peakVO2 and NT-proBNP
remained predictive in patients without beta-blocker treat-
ment. In contrast, in the beta-blocker group, only peakVO2
and LVEF remained as independent risk predictors. Fur-
thermore, Kaplan-Meier analyses revealed that for all strata,
beta-blocker–treated patients showed a significantly better
outcome than did patients without beta-blocker treatment.
Most importantly, the beta-blocker–treated patients with an
unfavorable risk profile (e.g., peakVO2 14 ml/min per kg)
showed a cardiac event rate comparable to that of patients
without beta-blocker treatment, as well as a relatively low
risk profile (e.g., peakVO2 14 ml/min per kg) (Fig. 3).
DISCUSSION
This study indicates that the predictive value of variables
used for risk stratification in CHF is markedly influenced by
the use of beta-blocker treatment. In particular, those
patients with advanced CHF and an unfavorable risk profile
benefited the most from beta-blocker treatment.
Total study group. Our study group, in which most
patients were in NYHA functional class II or III and had a
mean LVEF 22  10%, was comparable to those study
groups in several controlled trials, such as the Studies Of
Left Ventricular Dysfunction, Vasodilator-Heart Failure
Trial II and MEtoprolol CR/XL Randomized Intervention
Trial in congestive Heart Failure (3,17,18). This is also
reflected by a similar one-year mortality rate of 12% and a
hospitalization rate of 19% for worsening CHF in the total
study group. Furthermore, the classic predictors of CHF
prognosis—LVEF (11) and peakVO2 (19–22)—allowed us
to independently predict the cardiac event rate in the total
patient group. In agreement with previous studies on the
predictive value of natriuretic peptides (23), multivariate
analysis revealed NT-proBNP as another independent risk
predictor.
Comparison of two subgroups with respect to additional
beta-blocker treatment. Although the present study does
not fulfill the criteria of a randomized, controlled trial, an
equivalent risk may be assumed for both subgroups, as they
did not differ in mean NYHA functional class, age, gender
or peakVO2. The modestly lower heart rate and the slightly
higher LVEF in the beta-blocker group are in close agree-
ment with the responses previously observed under treat-
ment with beta-blockers at dosages (i.e., between 25% and
50% of the maximal recommended study doses) equivalent
to the mean dosages used in the present study (24). As
patients with CHF and ischemic heart disease have a worse
Table 3. Cox Regression Analysis
All
Patients
Patients Without
Beta-Blocker
Treatment
Patients With
Beta-Blocker
Treatment
Univariate analysis
NT-proBNP 49.2; 0.0001 33.5; 0.0001 10.3; 0.0014
PeakVO2 31.6; 0.0001 21.5; 0.0001 10.6; 0.0011
LVEF 30.1; 0.0001 13.9; 0.0002 11.9; 0.0006
NE 9.9; 0.0017 3.8; 0.0514 2.3; 0.1315
Beta-blocker
treatment
13.4; 0.0002 — —
Multivariate analysis
PeakVO2 12.2; 0.0005 9.2; 0.0024 4.1; 0.0425
LVEF 9.5; 0.0021 1.8; 0.1837 7.7; 0.0054
NT-proBNP 8.1; 0.0045 9.3; 0.0023 0.1; 0.7290
Data are presented as the chi-square statistic; p value.
Abbreviations as in Table 1.
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Figure 3. Kaplan-Meier analyses of patients with congestive heart failure treated with or without beta-blockers, stratified by (A) peak oxygen consumption (peakVO2) ( or 14 ml/min per kg), (B) left
ventricular ejection fraction (LVEF) ( or 20%) and the median values of (C) norepinephrine and (D) N-terminal pro-brain natriuretic peptide (NT-proBNP) (all p  0.0001).
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prognosis than those with dilated cardiomyopathy, the
higher proportion of patients with ischemic cardiomyopathy
in the beta-blocker–treated group may have slightly in-
creased the risk in this subgroup. Consistent with previous
reports on patients with CHF, the mean plasma concentra-
tions of NE (25) were about 25% lower in beta-blocker–
treated patients than in those without beta-blocker treat-
ment. Mean NT-proBNP was 22% lower in the beta-
blocker group, but failed to reach statistical significance,
because of marked variations within both groups.
Impact of beta-blocker treatment on cardiac event rate.
The present study was based on the assumption that the
beneficial effects of beta-blocker treatment on mortality and
morbidity are still demonstrable under routine clinical
conditions. Although patients treated with beta-blockers
received only 40% of the maximal recommended study
dosages, beta-blocker–treated patients had a 65% lower
one-year mortality rate than did patients without beta-
blocker therapy (6% vs. 17%). This low mortality rate closely
corresponds to that achieved in patients included into three
major beta-blocker trials (7). Likewise, the annual rate of
hospital admission due to worsening CHF was 50% lower in
patients with than in those without beta-blocker treatment
(12% vs. 24%). Because of the low event rate with beta-
blocker therapy, a combined end point—cardiac death or
hospital admission for worsening CHF—was used for
further analysis. The combined end point was observed in
16% of the patients receiving a beta-blocker and in 34% of
the patients without beta-blocker treatment. The beneficial
effect of beta-blocker therapy on the hospitalization rate and
cardiac mortality was seen throughout the total patient
group (Fig. 3).
Prognostic variables and beta-blocker treatment.
PeakVO2 is currently used as a “reference standard” for
selection of heart transplant candidates (6,16), with
peakVO2 14 ml/min per kg usually regarded as a critical
value. However, despite a similar mean peakVO2 in both
groups, the end-point rate was significantly lower in beta-
blocker–treated patients. For any given peakVO2 value,
beta-blockade was associated with a better prognosis. Even
in patients with the worst prognosis (i.e., peakVO2 10
ml/min per kg), one-year mortality was only 17% in
beta-blocker–treated patients, which is much lower than the
38% annual mortality rate in corresponding patients without
beta-blocker treatment.
Given the low mortality rates in high-risk patients treated
with a beta-blocker, a new definition of the optimal cut-off
value of peakVO2 may be warranted in the beta-blocker era.
For the other risk predictors also (i.e., LVEF, NE and
NT-proBNP), the impact of beta-blocker treatment on
prognosis was higher than expected from its effect on each
variable, as for any given value, the end-point rate was
markedly lower in beta-blocker–treated patients.
Study limitations. The present study is based on the
prospective collection of risk predictors in consecutive pa-
tients in a single-center CHF registry. Thus, there might be
a selection bias, as the center was a transplant referral site.
The mean age of the included patients was relatively low,
and the proportion of patients with ischemic heart disease
was lower than the proportion of patients who had dilated
cardiomyopathy. Because beta-blocker therapy has become
mandatory in symptomatic patients with CHF (5,6), it is no
longer ethically feasible to conduct a randomized trial.
Furthermore, with the emphasis on the assessment of the
impact of beta-blockade on the prognostic value of risk
predictors, a strict randomization is not a prerequisite, as the
major conclusions are based on the end-point rate observed
for a certain range of a risk predictor (e.g., peakVO2 10
ml/kg per min). In addition, it was an important aim of the
current study to draw conclusions from “real-life” practice,
which is also reflected by beta-blocker doses below the
maximal study doses. However, the present study does not
allow us to rule out that a higher beta-blocker dose might
have been associated with an even better prognosis. Finally,
as the follow-up was limited to one year, no reliable
statements on long-term prognosis are possible.
Clinical implications. In patients admitted to the hospital
with refractory heart failure and dependent on intravenous
inotropic agents or short-term mechanical circulatory sup-
port, there is little doubt that heart transplantation improves
their survival. However, heart transplantation is still associ-
ated with a 15% mortality rate in the first year (26). Thus,
it does not necessarily improve the outcome in every patient
with severe CHF (27). The present study indicates that the
prognostic impact of variables used for risk stratification in
CHF is markedly influenced by the use of beta-blocker
treatment. Therefore, a re-evaluation of the current criteria
for risk stratification in patients with CHF, including
treatment of CHF, is warranted.
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